Scientific meetings with external peer review

2019

R. Schäfer, D. Hernandez, M. Schlander:
Cancer-related HTA outcomes by European HTA agencies: a comparative analysis of G-BA, HAD and NICE.
Poster presentation to ISPOR 2019.
Copenhagen, Denmark. November 4, 2019.

J. Ubels, M. Schlander, K. Hernandez Villafuerte:
The dynamics between capability and wellbeing.
Oral Presentation to the Conference Defining the Value of Medical Interventions-Normative and Empirical Challenges.
Fürth, Germany. September 16-20, 2019.

M. Schlander:
Social Cost Value Analysis for HTA
Oral Presentation to the Health Technology Assessment international (HTAi) Conference.
Panel Session: PN35 - HTA, Social Preferences Measurement, And (Ultra) Rare Disorders: Social Cost Value Analysis For HTA.
Cologne, Germany. June 15-19, 2019.

C.-Y. Cheng, T. Ran, M. Schlander:
Are the colorectal cancer screening methods used in Germany cost-effective? A systematic review of European studies.
Poster presentation to 1st German Cancer Research Congress 2019 (DKFK).
Heidelberg, Germany. February 4-5, 2019.
Congress Program Booklet, Heidelberg, Germany. February 2019: P005, p. 15.

M. Schlander, K. Hernandez Villafuerte, C. Thielscher:
The economic burden of cancer in Germany.
Poster presentation to 1st German Cancer Research Congress 2019 (DKFK).
Heidelberg, Germany. February 4-5, 2019.
Congress Program Booklet, Heidelberg, Germany. February 2019: P103, p. 29.

M. Schlander, D. Hernandez, J. Richardson, O. Schwarz, C. Thielscher:
Measuring health related quality of life for economic analysis and Health Technology Assessment (HTA): why should we exercise caution when using generic Multi-Attribute Utility (MAU) measurement instruments.
Poster presentation to 1st German Cancer Research Congress 2019 (DKFK).
Heidelberg, Germany. February 4-5, 2019.
Congress Program Booklet, Heidelberg, Germany. February 2019: P102, p. 29.

J. Mader, K. Hernandez Villafuerte:
Inequalities in cancer incidence among German districts: A spatial analysis exploring the role of behavioral and socioeconomic factors.
Poster presentation to 1st German Cancer Research Congress 2019 (DKFK).
Heidelberg, Germany. February 4-5, 2019.
Congress Program Booklet, Heidelberg, February 2019: P024, p. 18.

2018

M. Schlander, H. Telser, B. Fischer, T. von Rechenberg, R. Schäfer:
Should rarity matter? Results of a social willingness-to-pay study using the discrete choice experiment (DCE) method in Switzerland.
Poster Presentation to ISPOR 21st Annual European Congress 2018.
Barcelona, Spain. November 10–14, 2018.

C.-Y. Cheng, T. Ran, M. Schlander:
A systematic review update on cost-effectiveness of colorectal cancer screening: Identification of an optimal strategy in Europe.
Poster presentation to National Cancer Research Institute (NCRI) Cancer Conference 2018.
Glasgow, Scotland. November 4-6, 2018.
British Journal of Cancer (2018) 119 (Supplement 1) 7.

M. Schlander:
Kostenintelligenz im Gesundheitswesen: massgeschneiderte Erstattung für massgeschneiderte Therapien ["Cost intelligence in health care: tailor-made reimbursement for targeted therapies"].
Invited presentation to 7th Annual Meeting of House of Pharma & Healthcare.
Frankfurt a.M., Germany. September 10-11, 2018.

M. Schlander, D. Hernandez, R. Schäfer, O. Schwarz:
What are the drivers of the value of a statistical life year? An analysis of empirical economic studies from 1995 to 2015.
Oral Presentation to 12th European Conference on Health Economics (EuHEA).
Maastricht, Netherlands. July 14, 2018.

M. Schlander, H. Telser, B. Fischer, T. von Rechenberg, R. Schäfer:
Attributes of health interventions that drive social willingness-to-pay: Evidence from a discrete choice experiment.
Oral presentation to 12th European Conference on Health Economics (EuHEA).
Maastricht, Netherlands July 13, 2018.

J. Mestre-Ferrandiz, P. Anderson, T. Davis, J. Espin, S. Flostrand, B. Godman, A. Hutchings, C. Jommi, J. Mestre-Ferrandiz, A. Parnaby, M. Schlander:
Forecasting pharmaceutical expenditure in Europe: Adjusting for the impact of rebates and discounts.
Poster presentation to 12th European Conference on Health Economics (EuHEA)
Maastricht, Netherlands. July 12, 2018.

B. Fischer, R. Schäfer, M. Schlander, H. Telser, T. von Rechenberg:
Hypothetical bias and the role of information in discrete choice experiments.
Poster presentation to 12th European Conference on Health Economics (EuHEA).
Maastricht, Netherlands. July 12, 2018.

K. Hernandez-Villafuerte, B. Zamora, Y. Feng, D. Parkin, N. Devlin, A. Towse:
Issues on the Estimation of the Opportunity Cost Threshold Value.
Poster presentation to the XXXVIII Spanish Health Economics Association Conference.
Las Palmas de Gran Canaria, Spain. June 20-22, 2018.

K. Hernandez-Villafuerte, J. Ubels, D. Hernandez, M. Schlander:
Efficacy of the multi-attribute utility instruments to reflect quality of life of cancer patients.
Poster presentation to Health Technology Assessment international (HTAi) Conference.
Vancouver, Canada. June 1-5, 2018.
International Journal of Technology Assessment in Health Care, (2018) 34(S1), 103.

K. Hernandez-Villafuerte, B. Zamora, Y. Feng, D. Parkin, N. Devlin, A. Towse:
Issues on the estimation of the opportunity cost threshold value.
Poster presentation to Health Technology Assessment international (HTAi) Conference.
Vancouver, Canada. June 1-5, 2018.
International Journal of Technology Assessment in Health Care, (2018) 34(S1), 115-116.

S. Bakshi, O. Sola-Morales, H. Telser, M. Schlander, D. Moro:
Social preferences in HTA: A discrete choice experiment (DCE) pilot analysis in CLN2 disease.
Poster presentation to Health Technology Assessment international (HTAi) Conference.
Vancouver, Canada. June 1-5, 2018.
International Journal of Technology Assessment in Health Care, (2018) 34(S1), 146-147.

M. Schlander, O. Schwarz, D. Hernandez, R. Schäfer:
The search for a cost effectiveness standard: 1-3 times GDP/Capita?
Poster presentation to Health Technology Assessment international (HTAi) Conference.
Vancouver, Canada. June 1-5, 2018.

M. Schlander, H. Telser, B. Fischer, T. von Rechenberg, R. Schäfer, and the ESPM Project Group:
Social preferences for health care interventions: The SoPHI ("Social Preferences for Health Care Interventions") study.
Poster presentation to Health Technology Assessment international (HTAi) Conference.
Vancouver, Canada. June 4, 2018.

M. Schlander, R. Gatermann:
Economical Perspectives in Rare Diseases.
Conference Theme 5 for European Conference on Rare Diseases & Orphan Products (ECRD).
Vienna, Austria. May 10-12, 2018.
[M. Schlander and R. Gatermann were also serving as a members of the scientific program committee for the conference]

M. Schlander, M. Toumi, J. Richardson, S. Upadhyaya:
A paradigm shift in value frameworks for access?
Invited Symposium presented to European Conference on Rare Diseases & Orphan Products (ECRD).
Vienna, Austria. May 10-12, 2018.

M. Schlander:
Economical Perspectives in Rare Diseases: "A Paradigm Shift in Value Frameworks for Access".
Invited presentation to European Conference on Rare Diseases & Orphan Products (ECRD).
Vienna, Austria. May 10-12, 2018.

M. Schlander, H. Telser, B. Fischer, T. von Rechenberg, R. Schäfer:
Drivers of social value exceed length and quality of life: evidence from Switzerland.
Poster presentation to ISPOR 23rd Annual International Meeting 2018, session on "Health Care Use & Policy Studies".
Baltimore, USA. May 22, 2018.
Value in Health, (2018) 21(Supplement1) S115.

M. Schlander, O. Schwarz, D. Hernandez, R. Schäfer:
New estimates of the willingness-to-pay for a statistical life year: A systematic review of the empirical economic literature.
Poster presentation to ISPOR 23rd Annual International Meeting 2018, session on "Health care use & policy studies".
Baltimore, USA. May 22, 2018.
Value in Health, (2018) 21(Supplement1) S111.

M. Wagner, D. Samaha, R. Casciano, M. Brougham, C. Petrie, P. Abrishami, B. Avouac, P. Kind, L. Mantovani, A. Sarría-Santamera, M. Schlander, M. Tringali:
Accountable and reasonable processes for coverage decision-making for rare disease and regenerative therapies: Which criteria should be considered and why?
Poster presentation to ISPOR 23rd Annual International Meeting 2018.
Baltimore, USA. May 21, 2018.
Value in Health, (2018) 21(Supplement1) S52.

2017

J. Espin, M. Schlander, C. Jommi, B. Godman, P. Anderson, J. Mestre-Ferrandiz, A. Hutchings, S.Flostrand, A. Parnaby:
Forecasting pharmaceutical expenditure in Europe: Adjusting from the impact of rebates and discounts?
Poster presentation to ISPOR 20th Annual European Congress 2017, session on "Health Care Use & Policy Studies".
Glasgow, UK. November 4-8, 2017.
Value in Health, (2017) 20(9) A664.

R. Schäfer, O. Schwarz, M. Schlander:
Appraising the appraisers: Do national Health Technology Assessment agencies (NICE, GBA/ IQWIG) follow their official evaluation criteria?
Poster presentation to ISPOR 20th Annual European Congress, session on "Health Technology Assessment Studies".
Glasgow, UK. November 4-8, 2017.
Value in Health, (2018) 20(9) A410.

M. Schlander, R. Schäfer, O. Schwarz:
Empirical studies on the economic value of a statistical live year (VSLY) in Europe: What do they tell us?
Poster presentation to ISPOR 20th Annual European Congress 2017, session on "Health Care Use & Policy Studies".
Glasgow, UK. November 4-8, 2017.
Value in Health, (2017) 20(9) A666.

J.J. Caro, A. McGuire, J. Brazier, M. Schlander:
Determining Value in Health Technology Assessment Consistent with Societal Aims: Pursue New Options?
Break-Out Session presented to SPOR 20th Annual European Congress 2017.
Glasgow, UK. November 7, 2017.

M. Schlander:
From CUA to MCDA and SCVA.
Invited presentation to SPOR 20th Annual European Congress 2017.
Glasgow, UK. November 7, 2017.

I. Wiest, K. Obermann, C. Thielscher:
Drug cost containment and negotiation power.
Poster presentation to ISPOR 20th Annual European Congress.
Glasgow, UK. November 4-8, 2017.
Value in Health, (2017) 20(9) A676-A677.

R. Schaefer, M. Schlander:
Is NICE in the UK more "innovation-friendly" than IQWiG/GBA in Germany?
Oral presentation to 14th HTAi Annual Meeting 2017, session on "Country-specific and regional HTA".
Rome, Italy. June 20, 2017.
International Journal of Technology Assessment in Health Care, (2017) 33(S1) 43-44.

M. Schlander, R. Schaefer, O. Schwarz:
An update on the economic value of a statistical life year in Europe.
Oral presentation to 14th HTAi Annual Meeting 2017, session on "Economic evaluation and decision making (B)".
Rome, Italy. June 20, 2017.
International Journal of Technology Assessment in Health Care, (2017) 33(S1) 44.

M. Schlander, O. Schwarz, R. Schaefer:
The monetary value of statistical life year: A systematic review.
Oral presentation to 14th HTAi Annual Meeting 2017, session on "Economic evaluation and decision making (B)".
Rome, Italy. June 19, 2017.
International Journal of Technology Assessment in Health Care, (2017) 33(S1) 192-193.

Non-refereed presentations (selection)

2019

M. Schlander:
What does value mean in rare disease?
Presentation to Innovation Forum.
Oxford, UK. April 1, 2019.

M. Schlander:
Training “Health Economics”
Presentation to Grünenthal Talent Programme by Frankfurt School.
Frankfurt, Germany. March 27, 2019.

2018

M. Schlander:
Exploring the health economics of cancer and cancer care: Advances, challenges, and current issues.
Guest Lecture. Lecture series: "Aktuelle Themen der Gesundheitsökonomik".
University of Mannheim, Faculty of Economics.
Mannheim, Germany. October 10, 2018.

M. Schlander:
Kostenintelligenz: Das Gesundheitssystem im Spannungsfeld zwischen einer alternden Gesellschaft und steigenden Kosten. [Cost intelligence: The healthcare system in the field of tension between an aging society and rising costs]
Guest Lecture. 7th Jahrestagung House of Pharma & Healthcare.
Frankfurt, Germany. September 11, 2018.

M. Schlander:
Measuring health-related quality of life.
Oral presentation to Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWIG).
Köln, Germany. July 9, 2018.

M. Schlander:
Sustainability: budgetary impact and cost drivers for rare and ultra-rare diseases.
Invited Presentation to International Workshop on "Health Systems Resilience for Rare Diseases". European Reference Network (ERN) on Rare Diseases.
Paris, France. June 27, 2018.

2017

D. Rees, S. Shah, M. Schlander, A. Wildi, J. Cain, A. Angelis:
The Evolving Approach to Drug Value Assessment in Global Markets.
Educational Symposium presented to ISPOR 20th Annual European Congress.
Glasgow, UK. November 5, 2017.
Program Booklet, Glasgow 2017, p. 11.

K. Loth, N. Bedlington, N. Hedberg, N. Moll, M. Schlander:
Have a voice in the pricing debate: medicines pricing simulation.
Invited lunch symposium presented to European Health Forum Gastein (EHFG).
Bad Hofgastein, Austria. October 5, 2017.

M. Schlander:
Examples of early access around the world: Germany.
Oral presentation at Symposium on "Early Access to Innovative Treatments" organized by the Turkish Health Economics and Policy Association (HEPA).
Istanbul, Turkey. December 8, 2017.

M. Schlander:
Societal willingness to pay methodologies for high-value medicines for rare diseases.
Oral presentation at International Symposium on "Accessibility to High-Value Medicines" organized by London School of Hygiene & Tropical Medicine.
London, UK. December 6, 2017.

M. Schlander:
HTA im deutschen Medizinproduktemarkt: Prinzipien, Prozesse, exemplarische Umsetzung. [Health Technology Assessment (HTA) for medical products – how to cope with the increasing regulatory burden?].
MedTechDialog „Navigating the Perfect Storm: Kosten-Nutzen-Bewertung / HTA für Medizinprodukte" (invited presentation); Mannheim Medical Technology Cluster.
Mannheim, Germany. March 23, 2017.

M. Schlander:
Common principles for value determination and assessment.
Invited panel contribution to "Second multi-stakeholder symposium on improving access to rare disease therapies", Eurordis.
Brussels, Belgium. February 23, 2017.

to top